Remember When Provenge's Price Was Bold? Every New Cancer Drug In 2017 Cost $100,000 Or More
The price of new oncology brands doubled in the US from 2013 to 2017, bringing the median annual price to more than $160,000 last year, up from $79,000 in 2013, according to a new IQVIA report. Spending on cancer drugs in the US has doubled since 2012, reaching nearly $50bn in 2017.
You may also be interested in...
APAC Cancer Preparedness Varied, Late Diagnosis A Key Challenge
A new report on the preparedness of 10 APAC nations to tackle a mounting cancer burden identifies gaps that need to be addressed, saying that a focus on prevention and early diagnosis could help, while also touching on issues around regional drug availability.
A Wake For IDO: Bristol Ends Registrational Trials Of High-Priced Flexus Drug
Following termination of pivotal trials in three tumor types testing its in-house IDO inhibitor BMS-986205, Bristol says it is "working quickly" to assess the development of Opdivo with Incyte's epacadostat.
Many New Oncology Drugs In 2012, With Prices That Test The Limits
More than a dozen new molecular entities launched for the treatment of cancer in 2012, advancing care for seriously ill people, but many carry price tags of $100,000 per year or more for treatment, escalating debate over cost of care and how best to direct limited healthcare resources.